Alpha-T: An innovative decentralized (home-based) phase 2 trial of alectinib in ALK-positive (ALK+) solid tumors in a histology-agnostic setting.

Razelle Kurzrock,Amy R. MacKenzie,Adham Adel Jurdi,Basem Goueli,Walter Bordogna,Magalie Hilton,Erika Ferreira, V. Archer,Bettyna Brivet-Jones,Johannes Noe,Abba Elizabeth Theogaraj,Lincoln Pasquina,Christine M. Lovly

Journal of Clinical Oncology（2021）

引用 6|浏览3

暂无评分

摘要

TPS3155Background: Anaplastic lymphoma kinase (ALK) fusions are found in 3–8% of non-small cell lung cancers (NSCLC) and 0.2% of other tumor types. Alectinib is a selective, CNS-active ALK tyrosin...

查看译文

AI 理解论文

溯源树

样例

生成溯源树，研究论文发展脉络

Chat Paper

正在生成论文摘要